- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02466464
Microporous Polysaccharide Hemospheres Epistaxis
January 25, 2017 updated by: Oswaldo A Henriquez, Emory University
Use of Microporous Polysaccharide Hemospheres (MPH) in Management of Acute Epistaxis
The purpose of this study is to compare a new treatment for nosebleeds to the treatment that has been used for many years.
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Detailed Description
Nosebleeds are a common condition which affect many Americans every day.The standard treatment in this hospital for nosebleeds that do not resolve with squeezing the nose or nasal spray is to place a nasal packing (aka nasal tampon) into the nose.
This is an effective treatment in most cases, but patients may find it to be uncomfortable.
The investigators will be comparing the standard nasal packing with a new type of powder which may also stop nosebleeds.
Study Type
Interventional
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Georgia
-
Atlanta, Georgia, United States, 30308
- Emory University Department of Otolaryngology Clinic
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- acute epistaxis who have failed conservative measures (including application of pressure and application of oxymetazoline spray) and for which the Otolaryngology service has been consulted
- must be alert and oriented
- hemodynamically stable with a hemoglobin greater than 9 g/dL
- cooperative
Exclusion Criteria:
- unable to consent or cooperate
- history of hereditary hemorrhagic telengectasias
- hemophilia
- clotting factor deficiencies
- history of prior surgery for epistaxis control
- nasal trauma
- recent sinonasal surgery
- hemodynamic instability
- posterior bleed (as determined by Ear, Nose, Throat physician)
- visibly bleeding vessel
- allergy to product
- current diabetic ketoacidosis
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Microporous Polysaccharide Hemospheres (MPH)
Subjects with acute epistaxis will receive microporous polysaccharide hemospheres (Arista) powder.
In the event that Arista fails to assist in resolving nosebleed in 15 minutes, subjects will be promptly escalated to the control group and will receive Merocel.
|
Two grams of Arista powder will be placed into the nose followed by four minutes of pressure and a moustache dressing.
Other Names:
8 cm of Merocel dressing will be placed into one or both sides of your nose for the next three to five days and will then be removed by the physician.
Other Names:
|
Active Comparator: Merocel (Control)
Subjects with acute epistaxis will receive standard-of-care treatment, nasal tampon (Merocel).
In the event that Merocel fails to assist in resolving nosebleed in 15 minutes, subjects will be promptly escalated to the MPH group and will receive Arista powder.
|
Two grams of Arista powder will be placed into the nose followed by four minutes of pressure and a moustache dressing.
Other Names:
8 cm of Merocel dressing will be placed into one or both sides of your nose for the next three to five days and will then be removed by the physician.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of subjects with resolution of bleed
Time Frame: 15 minutes (average time to resolve bleeding)
|
Resolution of bleeding is determined by cessation of blood flow anteriorly from the nares as well as posteriorly in the pharynx.
This will be determined by the otolaryngology resident or attending managing the patient during the study.
|
15 minutes (average time to resolve bleeding)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time until resolution of bleeding
Time Frame: 15 minutes (average time to resolve bleeding)
|
Number of minutes it takes to resolve bleeding comparing the Arista powder group versus the Merocel tampon group.
|
15 minutes (average time to resolve bleeding)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Oswaldo Henriquez Ajami, MD, Emory University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2015
Primary Completion (Actual)
December 31, 2015
Study Completion (Actual)
December 31, 2015
Study Registration Dates
First Submitted
June 5, 2015
First Submitted That Met QC Criteria
June 5, 2015
First Posted (Estimate)
June 9, 2015
Study Record Updates
Last Update Posted (Estimate)
January 26, 2017
Last Update Submitted That Met QC Criteria
January 25, 2017
Last Verified
January 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB00070733
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Epistaxis
-
NasaClipEmergency Medical Innovations, LLCRecruiting
-
Bezmialem Vakif UniversityCompleted
-
Izmir Ataturk Training and Research HospitalCompletedTranexamic Acid | Anterior EpistaxisTurkey
-
University of ZurichCompletedNosebleed (Epistaxis) - Posterior or AnteriorSwitzerland
-
University Hospital, Strasbourg, FranceRecruitingEpistaxis, Anterior Ethmoid ArteryFrance
-
Buddhist Tzu Chi General HospitalUnknownInjury Due to Endoscopic Examination | Transnasal Endoscopy Induced Epistaxis | Transnasal Endoscopy Induced Nasal PainTaiwan
-
University of AlbertaCompleted
-
Combined Military Hospital, PakistanCompleted
-
University of British ColumbiaCompleted
Clinical Trials on Microporous Polysaccharide Hemospheres
-
Memorial Health University Medical CenterCompleted
-
Grupo Español de Rehabilitación MultimodalUniversidad de Zaragoza; Aragon Health Science InstituteRecruitingPostoperative SepsisSpain
-
ZS Pharma, Inc.CompletedHyperkalemiaUnited States, South Africa, Australia
-
Massachusetts Eye and Ear InfirmaryWithdrawnObstructive Sleep Apnea | Tonsillar Hypertrophy | Obstructive Sleep DisorderUnited States
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingChronic Kidney Diseases | Magnetic Resonance ImagingChina
-
Beijing Zhifei Lvzhu Biopharmaceutical Co., LtdActive, not recruiting
-
PfizerCompletedPneumococcal InfectionsUnited States
-
Aimei Vacin BioPharm (Zhejiang) Co., Ltd.Not yet recruitingMeningococcal MeningitisChina
-
Unity Health TorontoCompleted
-
Sanofi Pasteur, a Sanofi CompanyCompletedPertussis | Tetanus | Diphtheria | Meningitis | MeningococcemiaUnited States